I write about retail and cannabis.
The study by Ashley C. Bradford and W. David Bradford examined whether states with medical marijuana laws saw changes for prescription drugs among Medicare Part D enrollees. Their analysis covered data between 2007 to 2014 and found that patients did indeed substitute medical marijuana for FDA-approved prescription drugs in these states.
“Total estimated Medicaid savings associated with these laws ranged from $260.8 million in 2007 to $475.8 million in 2014,” the study states. Granted this is only 2% of the total Medicaid drug spending for 2014, which was $23.9 billion, but it is still substantial savings. The Bradfords estimate that if all states had legalized medical marijuana in 2014, “The national savings for fee-for-service Medicaid would have been approximately $1.01 billion.” This works out to an average per state savings of $19.825 million a year.
However, only 26% of Medicaid customers are enrolled in the fee-for-service program. The study notes that if they applied their analysis equally to Medicaid managed care, then the savings could jump to a whopping $3.89 billion. Again, this is only if all states legalized medical marijuana.
Granted the savings are mostly enjoyed by private insurers that run the plans, but the Bradfords suggest that state governments could reduce their payments to the insurers as prescription drug costs fall.
The study only looked at conditions that could be treated with medical marijuana and the prescription drugs that would be affected. This included anxiety, depression, glaucoma, nausea, pain, psychosis, seizures, sleep disorders and spasticity. According to the study, “the differences ranged from a 42% reduction for prescriptions used to treat nausea to a 15% reduction for spasticity.” The Bradfords also found a 13% decline in depression drug prescriptions, a 12% drop in psychosis drug prescriptions and an 11% slide in pain drugs. There was no significant drop in drugs used for anxiety, glaucoma or sleep disorders.
The Bradfords noted that their study was challenged by the fact that states keep changing their medical marijuana laws and expanding approved conditions. Furthermore, they only had data available from fee-for-service Medicaid prescriptions. Managed care patient data was inconsistent. Thus, their findings are really lower than what the true savings could really be, suggesting it could be in the billions.
If you a German organization interested in partnering with one of the world’s leading producers of pharmaceutical grade cannabis, please send a confidential email to firstname.lastname@example.org for immediate consideration as a strategic and financial partner in the German BfArM application titled:
Medizinische Ausrüstungen, Arzneimittel und Körperpflegeprodukte
The Act on the Amendment of Drugs and Other Provisions, which entered into force on 10 March 2017, has expanded the scope for the prescription of cannabis medicines. The Act provides for the establishment of a government agency, the so-called cannabis agency, in accordance with the provisions of the United Nations Unity Treaty of 1961 on United Nations drugs. This will control and control the cultivation of cannabis for medical purposes in Germany.
Until cannabis is available for medical purposes from German cultivation, the demand is still covered by imports, for which the cannabis agency is not responsible (further information – see Bundesopiumstelle ).
The Cannabis Agency is a specialist area in the Department of Admission 4 (Special Therapies and Traditional Medicines) in the BfArM . It controls cultivation, harvesting, processing, quality testing, storage, packaging as well as delivery to wholesalers and pharmacists or manufacturers. The cannabis agency will take possession of the cannabis for medical purposes after the harvest.
The harvest is not transported to the BfArM , it is not stored there, nor is it redistributed from there. These steps will be located spatially at the respective construction companies or other commissioned companies.
The cultivation is therefore not carried out in the BfArM or by the BfArM itself, but by companies selected in a Europe-wide tender procedure and commissioned by the cannabis agency. The procedure takes into account all drug and narcotic drug requirements.
The tender procedure has now been published in the Official Journal of the European Union.
The following link leads to the tender documents: Supplement to the Official Journal of the European Union
Communication in connection with the tendering procedure takes place exclusively through the electronic award platform.
Cannabis will be grown exclusively for medical purposes. It is therefore a medicine. Only cannabis grown according to the guidelines of the Good Agricultural and Collection Practice (GACP ) will be used, which corresponds to the specifications of the Monograph “Cannabis Blossoms” ( DAB ) and the Requirements of the other relevant monographs and guidelines. This ensures the availability of cannabis for medical purposes in reproducible quality in accordance with drug laws. The cannabis for medical purposes is also subject to the provisions of the law on narcotic drugs.
The cannabis agency will set a manufacturer’s fee and sell the cannabis to cannabis drug manufacturers, wholesalers or pharmacies. The cannabis agency is not allowed to make any profits or surpluses. In the case of pricing, however, the personnel and material costs incurred by the BfArM are taken into account. However, the cannabis agency has no influence on the actual sales price in the pharmacy. The distribution channels of manufacturers and dealers will comply with the legal regulations and are thus identical with the regulations for the distribution of other drugs containing narcotic drugs.
Here you can find information about the cannabis agency and the cannabis cultivation of cannabis controlled by the cannabis agency for medical purposes:
Why must a so-called cannabis agency be established?
Where is the cannabis agency located?
What are the tasks of the cannabis agency?
What are the foundations of the tendering procedure?
How do I participate in the tender procedure?
Can you ask questions about the tender procedure?
How is the quality of the cannabis cultured in Germany to be used in the future?
The BERLIN PEACE ACCORDS, “putting an end to the world war on Cannabis” were ratified last week and are now available for your signature at http://www.berlinpeaceaccords.de
This is your chance to add your name to this historic document and tell the Presidents of the United States, the United Nations, the European Union as well as Chancellor Merkel of Germany that the world war on Cannabis needs to end in 2017.
BERLIN PEACE ACCORDS
BERLIN PEACE ACCORDS
12 April 2017
FOR IMMEDIATE RELEASE:
On the closing day of the International Cannabis Business Conference in Berlin, advocates from throughout the world ratified the BERLIN PEACE ACCORDS that call for an immediate end to the world war on cannabis.
On July 7, 2017 these Accords will be presented to President Donald Trump of the United States and Chancellor Angela Merkel of Germany at their summit meeting in Hamburg, Germany. In advance of that date, advocates worldwide will be showing their support by simply “liking” it on the facebook page: https://www.facebook.com/Berlin-PEACE-Accords-1899471536976478/
Citizens of the world who are in support of the BERLIN PEACE ACCORDS are urged to print these Accords off, sign them, place them at your home or office, and share them with others.
In addition, advocates will be re-posting these Accords on their respective facebook pages (and other social media) to have their members, customers, colleagues “like” the Accords as well.
If you are interested in becoming a “link on the chain” to peace or have any questions, please feel free to contact email@example.com for additional information or to support our efforts in anyway.
President Trump and Chancellor Merkel are interested to know if people in the year 2017 really feel this way.
Now is the time for you to show you do.
The Advocates of the
BERLIN PEACE ACCORDS
We the people of the Year 2017 do…
Hereby declare that it is our inalienable basic human right to have the freedom to grow, medicate and enjoy the plant we call Cannabis, without any governmental limitations.
We demand our plant has no more regulations or limitations than a tomato plant.
It is our basic human right to have control of what we choose to put into our body.
It is our basic human right to have the ability to enjoy this plant without fear of incarceration or limitations on its commerce.
It is our basic human right to have multiple ways to enjoy, grow and medicate with our plant and we demand that no commercial organization be provided exclusive use or rights.
For 10,000 years humans on our planet have enjoyed the benefits provided by our plant. With my signature below I do hereby attest it is my wish that “we the people” have the right to consume our plant as we wish.
LIKE THIS PAGE @
Thank you, Gracias und Dankeschoene,